Vistagen Therapeutics Files 8-K on Officer/Director Changes
Ticker: VTGN · Form: 8-K · Filed: Oct 29, 2025 · CIK: 1411685
| Field | Detail |
|---|---|
| Company | Vistagen Therapeutics, Inc. (VTGN) |
| Form Type | 8-K |
| Filed Date | Oct 29, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $3.90 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, corporate-governance, filing
Related Tickers: VTGN
TL;DR
Vistagen 8-K: Leadership changes and officer appointments filed 10/29.
AI Summary
Vistagen Therapeutics, Inc. filed an 8-K on October 29, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements. The filing also includes Regulation FD disclosures and financial statements/exhibits, with the earliest event reported as October 27, 2025.
Why It Matters
This 8-K filing indicates potential shifts in Vistagen's leadership and governance structure, which could impact the company's strategic direction and operational execution.
Risk Assessment
Risk Level: medium — Changes in directors or officers can signal internal shifts or strategic realignments that may carry inherent business risks.
Key Players & Entities
- Vistagen Therapeutics, Inc. (company) — Registrant
- October 27, 2025 (date) — Earliest event reported
- October 29, 2025 (date) — Date of report
- 343 Allerton Ave. (address) — Principal executive offices
- South San Francisco, California 94080 (address) — Principal executive offices location
FAQ
What specific officer or director positions were affected by the changes reported in this 8-K?
The filing indicates changes related to 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers,' but does not specify the names or exact roles affected in the provided text.
Are there any details regarding new compensatory arrangements for officers mentioned in the filing?
The filing lists 'Compensatory Arrangements of Certain Officers' as an item, but the specific details of these arrangements are not provided in the excerpt.
What is the significance of the 'Regulation FD Disclosure' item in this filing?
Regulation FD (Fair Disclosure) ensures that material non-public information is disclosed to all investors simultaneously, so this item suggests Vistagen is making such disclosures.
What types of financial statements and exhibits are included with this 8-K filing?
The filing states 'Financial Statements and Exhibits' are included, but the specific nature or content of these documents is not detailed in the provided text.
When was Vistagen Therapeutics, Inc. incorporated, and in which state?
Vistagen Therapeutics, Inc. was incorporated in Nevada.
Filing Stats: 1,000 words · 4 min read · ~3 pages · Grade level 10.9 · Accepted 2025-10-29 17:24:22
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share VTGN Nasdaq Capital Market
- $3.90 — ommon Stoc k"), at an exercise price of $3.90 per share, an amount equal to the closi
Filing Documents
- vtgn-20251027.htm (8-K) — 31KB
- ex101.htm (EX-10.1) — 59KB
- ex991.htm (EX-99.1) — 12KB
- picture1a.jpg (GRAPHIC) — 11KB
- 0001628280-25-047188.txt ( ) — 249KB
- vtgn-20251027.xsd (EX-101.SCH) — 2KB
- vtgn-20251027_lab.xml (EX-101.LAB) — 21KB
- vtgn-20251027_pre.xml (EX-101.PRE) — 12KB
- vtgn-20251027_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. A copy of the press release announcing Mr. Edick's appointment is attached to this Current Report on Form 8-K as Exhibit 99.1. The information under this Item 7.01 and Exhibit 99.1 attached hereto are intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Index Exhibit No. Description 10.1 Indemnification Agreement by and between Vistagen Therapeutics, Inc. and P. Edick, dated October 29 , 2025 99.1 Press Release issued by Vistagen Therapeutics, Inc., dated October 29, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Vistagen Therapeutics, Inc. Date: October 29, 2025 By: /s/ Shawn K. Singh Shawn K. Singh President and Chief Executive Officer